| 1. |
|
|
| 2. |
|
|
| 3. |
- Juliusson, Gunnar, et al.
(författare)
-
Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival.
- 2006
-
Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 37:5, s. 503-510
-
Tidskriftsartikel (refereegranskat)abstract
- Sixty-nine consecutive patients ( median age 54 years) were prospectively enrolled in a single-institution protocol for allogeneic transplantation with adjusted non-myeloablative fludarabine - melfalan-based conditioning including cyclosporin A and MMF, and one of three modes of serotherapy. Thirty-one donors (45%) were unrelated. The first cohort of 29 had ATG (Thymoglobulin 2 mg/kg x 3 days), the subsequent 26 had Campath 30 mg x 3 days subcutaneously, and the final cohort of 14 had 30 mg Campath once. The groups were similar as regards age, diagnosis and risk factors. Campath-patients had no acute toxicity, fewer days with fever and antibiotics, and required fewer transfusions than ATG-treated patients. 3-d-Campath patients showed lower lymphocyte counts from day +4, and CD4+, CD8+, CD19+ and NK cells recovered slower than in ATG-treated patients. More Campath patients developed mixed chimerism that required DLI. 3-d-Campath induced more serious and opportunistic infections than ATG, which resulted in a greater non-relapse mortality and an impaired overall survival despite a low tumor-related mortality. The change of the Campath dosing schedule to one dose abrogated the deleterious effect of 3-d-Campath on immune recovery, severe infections and survival. Subcutaneous Campath is simple and provides strong immune suppression with no early toxicity, but dose limitation to 30 mg once is recommended.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Malm, J U, et al.
(författare)
-
Chloroplast DNA haplotypes in Nordic Silene dioica: postglacial immigration from the east and the south
- 2005
-
Ingår i: Plant Systematics and Evolution. - : Springer Science and Business Media LLC. - 1615-6110 .- 0378-2697. ; 250:1-2, s. 27-38
-
Tidskriftsartikel (refereegranskat)abstract
- Analysis of PCR/RFLP variation in 57 Nordic populations of the herb Silene dioica, revealed 13 composite chloroplast DNA (cpDNA) haplotypes. The geographic distribution of the haplotypes suggests that the postglacial colonization of Fennoscandia by S. dioica may have involved immigration of populations from two main directions. The commonest cpDNA haplotype dominates in populations throughout most of Finland and northern and central Sweden, but is absent from southern Sweden. The distribution of this haplotype is interpreted in terms of immigration from an eastern or northern direction. In contrast, eight haplotypes that are absent from northern Fennoscandia are represented in populations in southern Sweden and in Denmark, suggesting colonization by populations derived from one or several refugial areas further to the south in Europe. The overall NE-SW pattern of cpDNA haplotype variation is similar to, but less diffuse than, the pattern revealed by allozyme markers.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Villa, Luisa L., et al.
(författare)
-
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
- 2006
-
Ingår i: Vaccine. - : Elsevier BV. - 1873-2518 .- 0264-410X. ; 24:27-28, s. 5571-5583
-
Tidskriftsartikel (refereegranskat)abstract
- Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved.
|
|
